Target: Nitrotyrosine
Conjugate: FITC
Product Type: Monoclonal
Clone Number: 39B6
Immunogen: 3-(4-hydroxy-3-nitrophenylacetamido) propionic acid-bovine serum albumin
Purification: Protein G Purified
Storage Buffer: PBS, 50% glycerol, 0.09% sodium azide *Storage buffer may change when conjugated
Concentration: 1 mg/ml
Specificity: Recognizes 3-nitrotyrosine moieties. No detectable cross-reactivity with non-nitrated tyrosine. Not species specific.
Scientific Background: Protein tyrosine nitration results in a post-translational modification that is increasingly receiving attention as an important component of nitric oxide signaling (2). While multiple nonenzymatic mechanisms are known to be capable of producing nitrated tyrosine residues, most tyrosine nitration events involve catalysis by metalloproteins such as myeloperoxidase, eosino-philperoxidase (3), myoglobin, the cytochrome P-450s, superoxide dismutase and prostacyclin synthase.Nitrotyrosine may also serve as a biomarker for the effects of reactive nitrogen oxides, based on tyrosine residues becoming nitrated in proteins at sites of inflammation induced tissue injury (1). The presence of nitro tyrosine-containing proteins therefore has shown high correlation to disease states such as atherosclerosis, Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (4).
References: 1. Girault I. et al. (2001). Free Radical Biology and Medicine, 31 (11): 1375-1387.2. Gow AJ, Farkouh CR, Munson DA, Posencheq MA, and Ischiropoulos H. (2004). Am J Physiol Lung Cell Mol Physiol. 287(2): L262-8.3. Takemoto K. et al (2007). Acta Med Okayama 61(1): 17-30.4. Reynolds MR. et al. (2006) J Nerosci. 26(42): 10636-45.5. Pfister H., et al. (2002) Vet Pathol. 39: 190-199.6. Khan J. et al. (1998) Biochem J. 330(2): 795-801.
Field of Use: Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.
English
Deutsch
